All news

Thermo Fisher cited as key contributor by ClearBridge

Alpha Vantage · Yahoo Finance · · AI-summarised by FinFlash

ClearBridge Investments' Large Cap Growth Strategy cited Thermo Fisher Scientific (NYSE: TMO) as a significant contributor in its Q3 2026 investor letter. The company benefited from strong second-quarter earnings, resilient biopharma and pharmaceutical product development markets, and healthy third-quarter guidance, pointing to an accelerating business outlook into 2027. The strategy's emphasis on quality and valuation proved advantageous amid volatility in higher-beta AI stocks. Analyst consensus stands at 22 Buy, 5 Hold and 1 Sell, with a $652.85 target versus a $676.76 price.

Read original source

TMO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.